Total synthesis and structural refinement of the cyclic tripyrrole pigment nonylprodigiosin

Journal of Organic Chemistry

Volumn 64, Issue 22, 1999, Pages 8275-8280

  Fürstner, Alois ^a   Grabowski, Jaroslaw ^a   Lehmann, Christian W ^a  

^a MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NONYLPRODIGIOSIN; PALLADIUM; PIGMENT; PYRROLE DERIVATIVE; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL REACTION; CHROMATOPHORE; CYCLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOSUPPRESSIVE TREATMENT; ISOMER; X RAY CRYSTALLOGRAPHY;

EID: 0038590297     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo991021i     Document Type: Article

References (89)

1. For a review of the early studies on prodigiosins see the following for leading references: (a) Castro, A. J. Nature 1967, 213, 903.
2. (b) Gerber, N. N. Crit. Rev. Microbiol. 1974, 3, 469 and references therein.
3. For previous synthetic studies on various prodigiosins, see inter alia (a) Hearn, W. R.; Elson, M. K.; Williams, B. H.; Medina-Castro, J. J. Org. Chem. 1970, 35, 142.
4. (b) Wasserman, H. H.; Lombardo, L. J. Tetrahedron Lett. 1989, 1725.
5. Rapoport, H.; Holden, K. G. J. Am. Chem. Soc. 1962, 84, 635.
6. Boger, D. L.; Patel, M. Tetrahedron Lett. 1987, 28, 2499.
7. (e) Boger, D. L.; Patel, M. J. Org. Chem. 1988, 53, 1405.
8. (f) Wasserman, H. H.; Rodgers, G. C.; Keith, D. D. J. Am. Chem. Soc. 1969, 91, 1263.
9. (g) Wasserman, H. H.; Keith, D. D.; Nadelson, J. J. Am. Chem. Soc. 1969, 91, 1264.
10. (h) Wasserman, H. H.; Keith, D. D.; Rodgers, G. C. Tetrahedron 1876, 32, 1855.
11. Wasserman, H. H.; Gosselink, E.; Keith, D. D.; Nadelson, J.; Sykes, R. J. Tetrahedron 1976, 32, 1863.
12. (j) Wasserman, H. H.; Keith, D. D.; Nadelson, J. Tetrahedron 1978, 32, 1867.
13. For preparation and the biological evaluation of prodigiosin analogues, see ref 1 and the following for leading references: (a) Brown, D.; Griffiths, D.; Rider, M. E.; Smith, R. C. J. Chem. Soc., Perkin Trans. 1 1986, 455.
14. (b) Blake, A. J.; Hunter, G. A.; McNab, H. J. Chem. Soc., Chem. Commun. 1990, 734.
15. Berner, H.; Schulz, G.; Reinshagen, H. Monatsh. Chem. 1977, 108, 233.
16. Berner, H.; Schulz, G.; Reinshagen, H. Monatsh. Chem. 1978, 109, 137.
17. (e) Berner, H.; Schulz, G.; Reinshagen, H. Monatsh. Chem. 1977, 108, 285.
18. (f) Berner, H.; Schulz, G.; Fischer, G.; Reinshagen, H. Monatsh. Chem. 1978, 109, 557.
19. (g) Castro, A. J.; Gale, G. R.; Means, G. E.; Tertzakian, G. J. Med. Chem. 1967, 10, 29.
20. (h) D'Auria, M.; De Luca, E.; Mauriello, G.; Racioppi, R. Synth. Commun. 1999, 29, 35.
21. (a) Lin, J. Immunol. Today 1993, 14, 290.
22. (b) Nakamura, A.; Nagai, K.; Ando, K.; Tamura, G. J. Antibiot. 1986, 39, 1155.
23. Tsuji, R. F.; Yamamoto, M.; Nakamura, A.; Kataoka, T.; Magae, J.; Nagai, K.; Yamasaki, M. J, Antibiot. 1990, 43, 1293.
24. Kataoka, T.; Magae, J.; Nariuchi, H.; Yamasaki, M.; Nagai, K. J. Antibiot. 1992, 45, 1303.
25. (e) Tsuji, R. F.; Magae, J.; Yamashita, M.; Nagai, K.; Yamasaki, M. J. Antibiot. 1992, 45, 1295.
26. (f) Kataoka, T.; Magae, J.; Kasamo, K.; Yamanishi, H.; Endo, A.; Yamasaki, M.; Nagai, K. J. Antibiot. 1992, 45, 1618.
27. (g) Kataoka, T.; Muroi, M.; Ohkuma, S.; Waritani, T.; Magae, J.; Takatsuki, A.; Kondo, S.; Yamasaki, M.; Nagai, K. FEBS Lett. 1995, 359, 53.
28. (h) Lee, M.-H.; Yamashita, M.; Tsuji, R. F.; Yamasaki, M.; Kataoka, T.; Magae, J.; Nagai, K. J. Antibiot. 1998, 51, 92.
29. Han, S. B.; Kim, H. M.; Kim, Y. H.; Lee, C. W.; Jang, E.-S.; Son, K. H.; Kim, S. U.; Kim, Y. K. Int. J. Immunopharmacol. 1998, 20, 1.
30. (j) Sato, T.; Konno, H.; Tanaka, Y.; Kataoka, T.; Nagai, K.; Wasserman, H. H.; Ohkuma, S. J. Biol. Chem. 1998, 273, 21455.
31. (k) Nakamura, A.; Magae, J.; Tsuji, R. F., Yamasaki, M.; Nagai, K. Transplantation 1989, 47, 1013.
32. Songia, S.; Mortellaro, A.; Taverna, S.; Fornasiero, C.; Schreiber, E. A.; Erba, E.; Colotta, F.; Mantovani, A.; Isetta, A.-M.; Golay, J. J. Immunol. 1997, 158, 3987.
33. 1 phase, mostly downstream from the interaction of IL-2 with its receptor, cf. ref 5.
34. These different mechanisms of action also suggest that a combined use of these drugs may be possible, permitting the use of relatively low concentrations of each drug and thereby potentially reducing toxicity, cf. ref 5.
35. 50 of 1 was reported to be 1.5 mg/kg i.p. for 6 days, while toxic signs are appreciable from a dose of 4mg/kg, cf. ref 5.
36. Rizzo, V.; Morelli, A.; Pinciroli, V.; Sciangula, D.; D'Alessio, R. J. Pharm. Sci. 1990, 88, 73.
37. (a) Magae, J.; Miller, M.; Nagai, K.; Shearer, G. M. J. Antibiot. 1996, 49, 86.
38. (b) Abe, F.; Morimoto, M.; Shibuya, K.; Yamazaki, M.; Nishigori, T.; Saito, S.; Shimada, N. Jpn. Kokai Tokkyo Koho JP 02, 250, 828 [90, 250, 828], 08 Oct 1990. Chem. Abstr. 1990, 114, 108967g.
39. For recent syntheses of these compounds from our laboratory see: Fürstner, A.; Szillat, H.; Gabor, B.; Mynott, R. J. Am. Chem. Soc. 1998, 120, 8305.
40. (b) For a synthesis of the structurally related alkaloid roseophilin see: Fürstner, A.; Weintritt, H. J. Am. Chem. Soc. 1998, 120, 2817.
41. (a) Gerber, N. N. Tetrahedron Lett. 1970, 809.
42. (b) Gerber, N. N. J. Antibiot. 1971, 24, 636.
43. Gerber, N. N. J. Heterocycl. Chem. 1973, 10, 925.
44. For recent reviews on RCM see the following for leading references: (a) Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413.
45. (b) Fürstner, A. Top. Catal. 1997, 4, 285.
46. Schuster, M.; Blechert, S. Angew. Chem., Int. Ed. Engl. 1997, 36, 2036.
47. Fürstner, A. Top. Organomet. Chem. 1998, 1, 37.
48. For RCM-based macrocycle syntheses from our laboratory see: (a) Fürstner, A.; Langemann, K. J. Org. Chem. 1996, 61, 3942.
49. (b) Fürstner, A.; Langemann, K. Synthesis 1997, 792.
50. Fürstner, A.; Kindler, N. Tetrahedron Lett. 1996, 37, 7005.
51. Fürstner, A.; Langemann, K. J. Org. Chem. 1996, 61, 8746.
52. (e) Fürstner, A.; Müller, T. Synlett 1997, 1010.
53. (f) Fürstner, A.; Langemann, K. J. Am. Chem. Soc. 1991, 119, 9130.
54. (g) Fürstner, A.; Gastner, T.; Weintritt, H. J. Org. Chem., 1999, 64, 2361.
55. (h) Fürstner, A.; Müller, T. J. Org. Chem. 1998, 63, 424.
56. Fürstner, A.; Seidel, G.; Kindler, N. Tetrahedron, 1999, 55, 8215.
57. (j) Fürstner, A.; Müller, T. J. Am. Chem. Soc. 1999, 121, 7814.
58. For RCM-based total syntheses of natural products from other groups see the following for leading references: (a) Nicolaou, K. C.; King, N. B.; He, Y. Top. Organomet. Chem. 1998, 1, 73.
59. (b) Hoveyda, A. H. Top. Organomet. Chem. 1998, 1, 105.
60. Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. J. Am. Chem. Soc. 1998, 118, 9606.
61. Bertinato, P.; Sorensen, E. J.; Meng, D.; Danishefsky, S. J. J. Org. Chem. 1996, 61, 8000.
62. (e) Martin, S. F.; Humphrey, J. M.; Ali, A.; Hillier, M. C. J. Am. Chem. Soc. 1999, 121, 866.
63. (f) Magnier, E.; Langlois, Y. Tetrahedron Lett. 1998, 837.
64. (g) Kim, S. H.; Figueroa, I.; Fuchs, P. L. Tetrahedron Lett. 1997, 38, 2601.
65. (h) Irie, O.; Samizu, K.; Henry, J. R.; Weinreb, S. M. J. Org. Chem. 1999, 64, 587.
66. Arakawa, K.; Eguchi, T.; Kakinuma, K. J. Org. Chem. 1998, 63, 4741.
67. (j) May, S. A.; Grieco, P. A. Chem. Commun. 1998, 1597.
68. D'Alessio, R.; Rossi, A. Synlett 1996, 513.
69. Nicolaou, K. C.; Claremon, D. A.; Papahatjis, D. P. Tetrahedron Lett. 1981, 22, 4647.
70. Greenhouse, R.; Ramirez, C.; Muchowski, J. M. J. Org. Chem. 1985, 50, 2961.
71. (a) For the borylation of N-Boc-pyrrole see: Martina, S.; Enkelmann, V.; Wegner, G.; Schlüter, A.-D. Synthesis 1981, 613.
72. (b) For a recent report on Pd(0)-catalyzed cross-coupling reactions of (N-Boc-pyrrol-2-yl)boronic acid see: Johnson, C. N.; Stemp, G.; Anand, N., Stephen, S. C.; Gallagher, T. Synlett 1998, 1025.
73. Review: (a) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457. For recent applications of Suzuki reactions from our laboratory see:
74. (b) Fürstner, A.; Seidel, G. Tetrahedron 1996, 51, 11165.
75. Fürstner, A.; Nikolakis, K. Liebigs Ann. 1996, 2107.
76. Fürstner, A.; Konetzki, I. J. Org. Chem. 1998, 63, 3072.
77. For a report on cross-coupling reactions using zincated 1-methylpyrrole, see: Minato, A.; Tamao, K.; Hayashi, T.; Suzuki, K.; Kumada, M. Tetrahedron Lett. 1981, 22, 5319.
78. (a) Nguyen, S. T.; Grubbs, R. H.; Ziller, J. W. J. Am. Chem. Soc. 1993, 115, 9858.
79. (b) See also: Schwab, P.; France, M. B.; Ziller, J. W.; Grubbs, R. H. Angew. Chem. 1995, 107, 2179.
80. 2OH is the diphenylallenylidene complex 19, cf. Harlow, K. J.; Hill, A. F.; Winton-Ely, J. D. E. T. J. Chem. Soc., Dalton Trans. 1999, 285, More detailed studies, however, have shown that the stable product formed is the rearranged product, i.e., the indenylidene ruthenium complex 20, cf. Hill, A. F.; Fürstner, A.; Liebl, M.; Mynott, R.; Gabor, B., Nolan, S. P. Manuscript in preparation.
81. 2OH is the diphenylallenylidene complex 19, cf. Harlow, K. J.; Hill, A. F.; Winton-Ely, J. D. E. T. J. Chem. Soc., Dalton Trans. 1999, 285, More detailed studies, however, have shown that the stable product formed is the rearranged product, i.e., the indenylidene ruthenium complex 20, cf. Hill, A. F.; Fürstner, A.; Liebl, M.; Mynott, R.; Gabor, B., Nolan, S. P. Manuscript in preparation.
82. (a) Fürstner, A.; Hill, A.; Liebl, M.; Winton-Ely, J. Chem. Commun. 1999, 601. For other studies on metathesis catalysts from our laboratory see:
83. (b) Fürstner, A.; Ackermann, L. Chem. Commun. 1998, 95.
84. Fürstner, A.; Picquet, M.; Bruneau, C.; Dixneuf, P. H. Chem. Commun. 1998, 1315.
85. Ackermann, L.; Fürstner, A.; Weskamp, T.; Kohl, F. J., Herrmann, W. A. Tetrahedron Lett. 1999, 40, 4787.
86. One recrystallization provides pure (E)-18 which was used for the X-ray analysis.
87. Falk, H.; Stressler, G.; Müller, N. Monatsh. Chem. 1988, 119, 505.
88. 2 = 0.234. For further information, see the Supporting Information. The complete set of data has been deposited at the Cambridge Crystallographic Data Center, Cambridge, UK, under the deposition number CCDC 121761.
89. The disorder originates from a 2-fold rotation of the macrocycle around an axis passing through the N-atom of the central pyrrole ring.